LONDON, January 11, 2019 /PRNewswire/ --
Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029
Biologics, Non-Biologics, NSAIDs, sDMARDs and Others
The global rheumatoid arthritis drugs market will reach $47bn in 2024. In 2018, the Biologics submarket held 87% of the Global Rheumatoid Arthritis Drugs market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 232-page report you will receive 234 charts- all unavailable elsewhere.
The 232-page report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
• Global Rheumatoid Arthritis Market from 2019-2029
• Forecast of the Global Rheumatoid Arthritis market by Submarket:
• Non-Biologics: NSAIDs, sDMARDs and Others
• Forecast of the leading drugs in the Global Rheumatoid Arthritis market:
• Simponi/Simponi Aria
• This report provides individual revenue forecasts to 2029 for these regional and national markets:
• North America: US, Canada
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia and rest of Europe
• Asia-Pacific: Japan, China, India and rest of Asia-Pacific
• Latin America: Brazil, Mexico, Rest of Latin America
• Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA
Each regional market is further segmented into Biologics, Non-Biologics, NSAIDs, sDMARDs and Others
• Our study discusses the selected leading companies that are the major players in the rheumatoid arthritis market:
• Eli Lilly
• Johnson & Johnson
• Merck & Co
• Our study discusses selected compounds under development for rheumatoid arthritis.
• This study provides a SWOT and STEP analysis of the rheumatoid arthritis drugs market.
Visiongain's study is intended for anyone requiring commercial analyses for the rheumatoid arthritis market. You find data, trends and predictions.
Buy our report today Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029: Biologics, Non-Biologics, NSAIDs, sDMARDs and Others
To request a report overview of this report please contact Sara Peerun at email@example.com or refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2019-2029/
Did you know that we also offer a report add-on service? Email firstname.lastname@example.org to discuss any customized research needs you may have.
Astellas Pharma Inc.
Bristol-Myers Squibb Company
Chugai Pharmaceutical Co Ltd.
Coherus BioSciences Inc
Dr Reddy's Laboratories
F. Hoffmann-La Roche Ltd (Roche)
Fujifilm Kyowa Kirin
Gilead Sciences Inc
Intas Pharmaceuticals Limited
Johnson and Johnson
LG Life Sciences
Mycenax Biotech Inc.
Regeneron Pharmaceuticals, Inc.
Shanghai CP Goujian Pharmaceutical Co
Sharp & Dhome
Van der Heijde
Other Organizations Mentioned in This Report
African League of Associations in Rheumatology
American College of Rheumatology
ANVISA (Agência Nacional de Vigilância Sanitária)
Canadian Arthritis Society
Centers for Disease Control and Prevention (CDC)
Committee for Medicinal Products for Human Use (CHMP)
Emirates Arthritis Foundation
European Medicines Agency
Government of Abu Dhabi
Institut fϋr Qualität und Wirtschaftlichkeit im Gesundheitswesen - IQWiG
Institute for Quality and Efficiency in Healthcare
International League of Associations for Rheumatology
Ministry of Health
National Center for Biotechnology Information
National Institute for Health and Care Excellence (NICE)
National Institute for Health Research (NIHR)
National Institute on Aging
National Rheumatoid Arthritis Society
National Treasury of Republic of South Africa
Servizio Sanitario Nazionale (SSN)
U.S. Food and Drug Administration (FDA)
Unified Health System
US Patent Office
World Arthritis Day
To see a report overview please e-mail Sara Peerun on email@example.com